The Life Sciences team advised HOOKIPA Pharma Inc. (Nasdaq: HOOK) on its underwritten public offering of 22,900,768 shares of its common stock and 15,268 shares of its non-voting Series A-2 convertible preferred stock. The public offering price of each share of common stock is $1.31 and the public offering price of each share of non-voting Series A-2 preferred stock is $1,310.00 (each share of non-voting Series A-2 preferred stock is convertible into 1,000 shares of common stock). The gross proceeds to HOOKIPA from this offering is approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering are to be sold by HOOKIPA. The offering closed on June 5, 2023.
HOOKIPA is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify T cells and thereby fight or prevent serious disease.
For more details, read the press release.